Insmed Incorporated (NASDAQ:INSM) Position Reduced by Susquehanna Portfolio Strategies LLC

Susquehanna Portfolio Strategies LLC reduced its position in Insmed Incorporated (NASDAQ:INSM) by 47.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,319 shares of the biopharmaceutical company’s stock after selling 10,100 shares during the period. Susquehanna Portfolio Strategies LLC’s holdings in Insmed were worth $758,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. First Horizon Advisors Inc. grew its position in Insmed by 83.4% during the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 287 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Insmed in the first quarter worth $33,000. Fidelis Capital Partners LLC purchased a new position in shares of Insmed during the first quarter valued at $34,000. CWM LLC raised its position in Insmed by 11.0% during the second quarter. CWM LLC now owns 1,570 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 155 shares during the period. Finally, Nisa Investment Advisors LLC lifted its stake in Insmed by 8.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 135 shares in the last quarter.

Insmed Stock Down 0.5 %

Shares of INSM stock opened at $72.48 on Friday. The stock’s 50 day simple moving average is $74.29 and its 200 day simple moving average is $53.43. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The company has a market capitalization of $10.77 billion, a price-to-earnings ratio of -13.86 and a beta of 1.11.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($1.94) EPS for the quarter, missing analysts’ consensus estimates of ($1.22) by ($0.72). The firm had revenue of $90.34 million for the quarter, compared to the consensus estimate of $87.95 million. During the same quarter last year, the company posted ($1.78) earnings per share. The firm’s revenue for the quarter was up 17.0% on a year-over-year basis. As a group, research analysts predict that Insmed Incorporated will post -5.42 EPS for the current year.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now directly owns 106,134 shares of the company’s stock, valued at $7,951,559.28. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Martina M.D. Flammer sold 13,436 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total value of $1,006,625.12. Following the sale, the insider now owns 106,134 shares in the company, valued at $7,951,559.28. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Michael Alexander Smith sold 27,871 shares of the business’s stock in a transaction on Friday, September 13th. The stock was sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the transaction, the insider now directly owns 67,856 shares in the company, valued at approximately $5,045,093.60. The disclosure for this sale can be found here. Insiders sold a total of 78,882 shares of company stock valued at $5,765,446 in the last quarter. Insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. StockNews.com cut Insmed from a “hold” rating to a “sell” rating in a research note on Friday, August 9th. Bank of America reiterated a “buy” rating and issued a $83.00 price objective on shares of Insmed in a research note on Friday, July 5th. Stifel Nicolaus increased their target price on shares of Insmed from $74.00 to $88.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Guggenheim boosted their price target on shares of Insmed from $70.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, July 9th. Finally, The Goldman Sachs Group increased their price objective on Insmed from $74.00 to $102.00 and gave the stock a “buy” rating in a report on Wednesday, July 10th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat, Insmed presently has an average rating of “Moderate Buy” and a consensus price target of $81.40.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.